China has administered more than one billion doses of its homegrown COVID-19 vaccines, the majority of which were developed by local companies Sinovac and Sinopharm. So what do we know about them?
Articles on Sinopharm
Displaying all articles
Infections have been reported in people vaccinated with the Sinopharm vaccine, but these aren’t necessarily unexpected.
What does the Seychelles experience tell us about variants, vaccine efficacy and herd immunity?
A vaccination queue-jumping scandal in Peru has caused a massive uproar in the South American country. It could also be a wake-up call for all nations.
With richer countries having bought up most of the leading western vaccines, others are looking to India, China and Russia for supplies.
A primer on Sinovac, Sinopharm and CanSino, and their prospects for achieving a world first for coronavirus.
Top contributors
-
Clinical researcher, Murdoch Children's Research Institute
-
Professor of Global Biosecurity, NHMRC L3 Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW
-
PhD Candidate, Research Ethics, University of Waterloo
-
Reader, Global Development Institute, University of Manchester
-
Senior Principal Research Fellow; paediatrician; infectious diseases epidemiologist; vaccinologist, The University of Melbourne
-
PhD candidate in Political Science, University of Glasgow
-
Assistant Professor, Department of Philosophy, University of Alberta
-
Senior Research Fellow in Global Health, University of Southampton
-
Professor of Innovation and Strategy, International Institute for Management Development (IMD)